REG - Uniphar PLC - Result of AGM

UnipharAnnouncement

12/05/2021 16:15

RNS Number : 4280Y
  
Uniphar PLC
  
12 May 2021
  
 

 
 
AGM Results
 
Dublin, London | 12 May 2021
 
 
Uniphar plc is pleased to announce that at the Annual General Meeting held at 11.00 a.m. today, 12 May 2021, each of the resolutions set out in the Notice of Annual General Meeting circulated to shareholders and made available on the Company's website, www.uniphar.ie, were duly passed without amendment.
 
Details of votes cast are set out below:
 







RESOLUTION


TOTAL


FOR


%


AGAINST


%


ABSTAIN




1


Financial Statements and Reports


137,296,226


135,574,392


98.75


1,721,834


1.25


20,532




2


Final Dividend of €4.2m


137,296,226


137,293,095


100.00


3,131


0.00


20,532




3(a)


Re-elect Tim Dolphin


137,316,758


137,242,840


99.95


73,918


0.05


0




3(b)


Re-elect Padraic Dempsey


137,316,758


137,242,840


99.95


73,918


0.05


0




3(c)


Re-elect Paul Hogan


137,316,758


136,410,522


99.34


906,236


0.66


0




3(d)


Re-elect Maurice Pratt


137,316,758


137,219,247


99.93


97,511


0.07


0




4(a)


Elect Jeff Berkowitz


137,316,758


137,284,424


99.98


32,334


0.02


0




4(b)


Elect Jim Gaul


137,316,758


137,284,424


99.98


32,334


0.02


0




4(c)


Elect Liz Hoctor


137,316,758


137,293,695


99.98


23,063


0.02


0




5


Remuneration of Auditors


125,264,944


119,641,181


95.51


5,623,763


4.49


12,051,814




6


Allot relevant securities


137,296,100


135,196,092


98.47


2,100,008


1.53


20,658




7


Disapplication of pre-emption rights in specified circumstances


137,264,600


137,241,537


99.98


23,063


0.02


52,158




8


Disapplication of pre-emption rights in additional circumstances


137,264,600


137,185,914


99.94


78,686


0.06


52,158




9


Authorise market purchases of the Company's Ordinary Shares


137,304,627


137,281,564


99.98


23,063


0.02


12,131




10


Re-issuance of Treasury Shares


137,304,627


137,281,564


99.98


23,063


0.02


12,131



 
 
--- ENDS ---
 
For further details contact:
 



Uniphar


+353 (0) 1 428 7777














Brian O'Shaughnessy








Group Director of Corporate Development


investor.relations@Uniphar.ie














 
Davy


 
+353 (0) 1 679 6363




(Joint Broker, Nominated Adviser and Euronext
Growth Adviser)


















Fergal Meegan








Barry Murphy








Niall Gilchrist


















RBC Capital Markets (Joint Broker)


+44 (0) 20 7653 4000














Jonathan Hardy








Jamil Miah
Priyal Soni
 








Stifel Nicolaus Europe Limited (Joint Broker)


+44 (0) 20 7710 7600




Matt Blawat








Ben Maddison








Francis North


















Q4 PR


+353 (0) 1 475 1444 or




(Public Relations Adviser to Uniphar)


+353 87 235 6461














Iarla Mongey







 
About Uniphar plc
 
Headquartered in Dublin, Ireland, Uniphar is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,600, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US.
 
The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.
 
Commercial & Clinical 
In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, Benelux, the Nordics and the US, the Group is growing with its clients to provide pan-European solutions. Uniphar has built a fully integrated multi-channel solution that is supported by our highly experienced and clinically trained teams leveraging our digital technology and insights which allows us to deliver consistently exceptional outcomes for our clients. 
 
Product Access 
n Product Access the Group is growing two distinct service offerings: 1) "On Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.
 
Supply Chain & Retail 
Uniphar is an established market leader in Ireland with over a 50% market share in the wholesale/hospital market, supported by a network of c.330 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are utilised for the benefit of the growth divisions, Commercial & Clinical and Product Access. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
RAGFLFLSEIIFLIL